1. Characterization of Noradrenergic Circuits and the Locus Coeruleus in Parkinson's Disease Progression

Investigation into the influence of the noradrenergic system on the basal ganglia during prodromal and advanced stages. This line integrates neuroanatomical, behavioral, and functional approaches to determine how the dysfunction of these circuits impacts the pathophysiology of the disease.

2. Early Detection via Biomarkers of Mitochondrial Activity, Inflammation, and Noradrenergic Function

Identification of central and peripheral biological indicators through proteomic, lipidomic, and microbiomic analysis. The aim is to establish specific pharmacological targets to enable intervention during the initial (prodromal) phases of the pathology.

3. Development of Nanotechnology Systems and Cell Therapies for Dopaminergic Protection and Regeneration

Integration of nanotechnology, neurotrophic factors, and cell therapies for a comprehensive approach to the disease. We investigate the efficacy of these systems in protecting dopaminergic neurons and preventing motor complications (dyskinesia) as well as non-motor symptoms in experimental stages.

4. Evaluation of the Potential Neuroprotective Role of the Cannabinoid CB2 Receptor

5. Interaction of the Gut-Brain Axis and its Impact on the Development of Neurodegenerative Pathologies

Study of the causal relationship between intestinal inflammation and neurodegeneration. Using murine models of ulcerative colitis, we analyze how gastrointestinal tract alterations may influence the onset and progression of Parkinson's disease.